Cardiovascular Presentation in Pheochromocytoma: What We Should be Aware

Amalia, Rizki; Dewi, Ivana Purnama; Wardhani, Louisa Fadjri Kusuma; Pikir, Budi Susetyo

doi:10.33192/smj.2022.9

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kalantar et al (2013) found that elevated platelet count and activation, as well as arrhythmias, appeared to be the most likely contributors to the occurrence of sudden cardiovascular events, including death, in cachexia patients. Patients with cachexia might develop atherosclerotic plaques, which can increase the risk of developing acute coronary syndrome and/ or death due to sudden cardiac diseases, as a result of increased platelet count and activation accompanied by endothelial dysfunction and increased pro-inflammatory cytokines (Molnar et al 2011, Fatkhullina et al 2016, Anaszewicz & Budzyński 2017, Amalia et al 2022. They could be more prone to developing arrhythmias, particularly atrial fibrillation (Arámbula-Garza et al 2016, Anaszewicz & Budzyński 2017.…”

Section: Discussionmentioning

confidence: 99%

Mortality among Heart Failure Patients in the Presence of Cachexia

Andrianto

Karman²,

Mudjanarko³

et al. 2023

FMI

View full text Add to dashboard Cite

Highlights: Around 38.8% of heart failure patients with cachexia died during the 180-1,876-day follow-up period. Cachexia increases the risk of mortality in heart failure patients. Abstract: Despite the fact that obesity has long been recognized as a risk factor for cardiovascular disease, the mortality rate of heart failure (HF) patients with cachexia is still high. Several studies have been conducted to investigate the association between cachexia and mortality in HF patients. However, the research results vary, as do the diagnostic criteria employed to assess cachexia. This meta-analysis aimed to conclusively summarize the association between cachexia and mortality in HF patients. The data were obtained from prospective or retrospective cohort studies with full texts in English or Indonesian and keywords related to "cachexia," "heart failure," and/ or "mortality". Studies that did not assess mortality in HF patients with cachexia and had no full text accessible were omitted. A literature search was conducted through four databases (PubMed, Web of Science, Scopus, and SAGE Journals) using keywords, reference searches, and/ or other methods on April 2022 in accordance with the Preferred Reported Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data from the selected studies were presented and analyzed using qualitative and quantitative synthesis methods. The Newcastle-Ottawa Scale (NOS) was used to assess the risk of bias in the selected cohort studies. The qualitative synthesis contained nine studies, whereas the quantitative synthesis (meta-analysis) included six studies. Cachexia was found in 16.0% of the 4,697 patients studied. During the 180-1,876-day follow-up period, 33.0% of the patients died, with a mortality rate of 38.8% among the patients with cachexia. The pooled analysis revealed cachexia to be a significant predictor of mortality in HF patients (hazard ratio (HR)=3.84; 95% CI=2.28-6.45; p<0.00001), but with significant heterogeneity (p<0.00001; I2=88%). In conclusion, cachexia worsens HF prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Mortality among Heart Failure Patients in the Presence of Cachexia

Andrianto

Karman²,

Mudjanarko³

et al. 2023

FMI

View full text Add to dashboard Cite

show abstract

Diagnosis and management of patients with pheochromocytoma/paraganglioma: Consensus of experts of the Russian Medical Society for Arterial Hypertension and the Multidisciplinary Group for the Diagnosis and Treatment of Neuroendocrine Tumors

Blinova,

Ilovayskaya,

Chikhladze

et al. 2024

Terapevticheskii arkhiv

View full text Add to dashboard Cite

The understanding of the nature of catecholamine-secreting tumors has changed significantly in recent years, affecting terminology and classification. Phaeochromocytoma/paraganglioma (PCC/PG) is a rare neuroendocrine tumor from chromaffin tissue that produces and secretes catecholamines. The incidence of PCC/PG is relatively low, with 2–8 cases per 1 million population per year; among patients with arterial hypertension, their prevalence is 0.2–0.6%. However, delayed diagnosis of PCC/PG is associated with a high risk of cardiovascular complications and a high mortality rate. The consensus presents the clinical manifestations of the disease with an emphasis on the course of arterial hypertension as the most common symptom in PCC/PG; modern ideas about the features of diagnosis, aspects of preoperative preparation, treatment, and follow-up of patients with PCC/PG are considered.

show abstract

Pheochromocytoma with Type 2 Diabetes Mellitus and Subclinical Cushing's Syndrome

Mawardi,

Mudjanarko,

Yunasan

2023

Biomolecular and Health Science Journal

View full text Add to dashboard Cite

Pheochromocytoma is a catecholamine-producing tumor that originates from adrenal medullary chromaffin cells. It affects 1–8 per million people annually and accounts for 5% of adrenal incidentalomas. Here, we report a 62-year-old man with sudden excessive sweating, palpitations, and headaches. He has a history of type 2 diabetes mellitus, hypertension, and an adrenal mass found incidentally by ultrasonography. Clinical history and further imaging suggest a pheochromocytoma; however, the presence of subclinical Cushing's syndrome and a normal urine vanillylmandelic acid level have led to diagnostic challenges. Finally, the patient underwent a left adrenalectomy. Histopathology showed the tumor as thick nests of cells, positive chromogranin A staining, and negative inhibin staining that confirmed the diagnosis of pheochromocytoma. In conclusion, our patient had pheochromocytoma that was thought to produce adrenocorticotropic hormone ectopically, resulting in subclinical Cushing's syndrome.

show abstract

Cardiovascular Presentation in Pheochromocytoma: What We Should be Aware

Cited by 3 publications

References 17 publications

Mortality among Heart Failure Patients in the Presence of Cachexia

Mortality among Heart Failure Patients in the Presence of Cachexia

Diagnosis and management of patients with pheochromocytoma/paraganglioma: Consensus of experts of the Russian Medical Society for Arterial Hypertension and the Multidisciplinary Group for the Diagnosis and Treatment of Neuroendocrine Tumors

Pheochromocytoma with Type 2 Diabetes Mellitus and Subclinical Cushing's Syndrome

Contact Info

Product

Resources

About